anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%-11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research-mechanistic, translational, and clinical-is urgently needed.
Cytarabine twice daily on Days 1, 3 and 5. Placebo with 1st cycle of high-dose consolidation therapy and Eltrombopag(dose and schedule as determined in Phase I) with 2nd cycle. Treatment sequence will be blinded to the patient and all study/sponsor personnel.
FIELD: molecular biology. SUBSTANCE: invention relates to the novel growth/differentiation factor of TGF-β-family and coding its DNA sequences. Invention involves mature protein site and if necessary other functional regions of nucleotide sequence indicated in SEQ ID NO,1, vector containing copy of DNA molecule by p. 1, cell-host transformed by DNA by p. 1, protein expressed by other cells, method of its preparing, pharmaceutical compositions including this protein and polyclonal antibodies raised to this protein. Invention ensures to obtain DNA sequences that encode the novel members of proteins of TGF-β-family showing osteogenic properties. EFFECT: new factor indicated above, improved method of preparing, valuable medicinal properties. 9 cl, 3 tbl, 2 dwg
Bupivacaine hydrogen chloride Inj 0.5%(1:200,000) epinephrine. 10ml injected for ultrasound guided Interscalene Brachial Plexus Block at C5 or C6.
Patients will be administered paracetamol 1 gr IV every 8 hours in the postoperative period. If patients' NRS score will ≥4/10, 100 mg IV tramadol will be performed.
Social media databases are minded for data related to a subject person. The data in indicative of a level of ultraviolet light exposure of the subject person. An ultraviolet violet exposure profile for the subject person is generated based upon the data and a health assessment report provided. The data may include timestamped images of the subject person and other related persons. The skin characteristics within images are analyzed to determine an ultraviolet light exposure level for the subject person from each image. The skin characteristics may include skin color, freckling and blemishing. The ultraviolet light exposure profile may be developed over an extended interval based upon the image timestamps. The health report may be used to mitigate risks, such as skin cancer, associated with exposure to ultraviolet light.
Pregnant women experiencing anxiety randomized to the Happy Mother Healthy Baby (HMHB) intervention receive a CBT-based psychosocial intervention (with six core and up to six booster sessions). HMHB is a facility-based intervention delivered by non-specialist providers. It is aimed to raise psychosocial awareness and facilitate positive change inter personal wellbeing, social support, and bonding with their baby during pregnancy. It addresses with relapse prevention, planning for the baby's arrival, and in management of emotional challenges in the early postnatal period. Family member/s will be invited to attend 3 core sessions.
The present invention relates to an antitoxic medicated thread for treating hepatitis B, which is prepared by soaking No. 2 or No. 3 catgut in medical liquid prepared from 11 kinds of traditional Chinese medicine, such as bupleurum, liquorice, isatis root, flavescent sophora root, cape jasmine fruit, etc. A majority of medicine of the present invention is cold in nature and bitter in taste; when entering the liver and gallbladder channels, the present invention has the effects of clearing away heat and toxins, dispersing stagnated liver qi for promoting bile flow, absorbing clots and removing stasis. The medicated thread is embedded into different acupuncture points according to symptoms, wherein effective medicine components can fully regulate the physiological function of an organism after being absorbed by the organism to perform the functions of dispersing stagnated liver qi for promoting bile flow, clearing away heat and toxins, comforting the spleen and regulating vital energy. Additionally, as foreign protein, the catgut has the function of optimal stimulation on acupuncture points, and the stimulation information acts on immune cells of the organism to reconstruct the active immunity function of the liver for inducing and generating substances, namely auto-interferon, which automatically resists hepatitis B virus; therefore, the present invention has the advantages of exterminating hepatitis B virus and improving the function of the liver.
PROBLEM TO BE SOLVED: To provide an oral auxiliary preparation by mixing zinc with ascorbic acid (vitamin C) so as to be palatable and not leave a disagreeable aftertaste and adding the mixture in the form of rhombic troche or similar oral preparation. SOLUTION: The oral composition comprises at least one zinc compound, at least one amino acid, an ascorbic acid raw material and a base agent material. The composition is dissolved in an oral cavity and gradually impregnated. The amino acid gives a palatable taste to one or more zinc compounds, but does not leave any aftertaste. The ascorbic acid raw material provides vitamin C without causing the mutual reaction of the ascorbic acid raw material with zinc and further without producing a non-palatable by-product. The obtained rhombic troche has a pleasant taste, does especially not have an astringent taste, and never leaves an aftertaste.
FIELD: ophthalmology. SUBSTANCE: buffered solution of heparin-copper ion complex at pH 7.4 is introduced into anterior chamber. One ml of solution contains 20 to 150 units of heparin and 0.001 to 0.003 mg of copper ions. Solution may be either injected or introduced by phonophoresis technique. As a result, corneal endothelium proliferation is activated owing to activation of endothelium proliferation stimulant - fibroblastic growth factor in Descemet's membrane. EFFECT: increased endothelium mobility. 3 cl, 3 dwg, 2 ex
The present invention relates to a composition having anti-coccidium activities which includes extract of magnolia officinalis. Technical characteristics of the present invention comprises: reducing coccidium oocyst and helping normal growth when the composition is administered into an entity which is infected by the coccidium. In addition, the composition has 86% or higher of cell survival rate when 100-200 uM concentration of the magnolia officinalis extract is applied based on 1x106 cells/ml of cell density. Also, if the composition is administered into the entity for long time and dose of the magnolia officinalis extract becomes 400mg/kg/day, cytotoxicity is not expressed. Also, the composition prevents, improves, and treats the coccidiosis caused by coccidia (Eimeria spp.).
The dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia [see Use in Specific Populations (8.4)]. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants. The infusion rate and volume should be determined by the consulting physician experienced in pediatric intravenous fluid therapy. 

In pediatric patients, TRAVASOL is dosed on the basis of protein provided as amino acids. The recommended dosage, by age group is provided in .

Infusion rates are based on protein and do not take carbohydrates, fluid or electrolytes into consideration.

TRAVASOL does not contain the amino acids cysteine and taurine, considered conditionally essential for neonates and infants. If possible, these amino acids should be added to the parenteral nutrition admixture if used in this pediatric population.
SHAM procedure is done one hour before cemented hip arthroplasty and comprises of 4 cycles of 5min sham procedure. Everything apart from the pressure in the cuff is similar to the RIPC procedure.
Three subjects determined to be eligible for study and agree to participate are assigned to receive 200 cGy of TSI-HT for 5 days. If this dose level is well tolerated in the first 3 subjects, the dose will be increased and given over 5 days. The dose will continue to be increased until the maximum toelrated dose is reached.
A vaccine for protecting poultry against Avian Encephalomyelitis, is prepared as follows: (1) Removal and treatment of brain tissue from an infected chick within 48 hours of onset of clinical symptoms; (2) Intracerebral injection of material thus obtained into a susceptible chick; (3) Removal and treatment of brain tissue from the thus-infected chick within 48 hours of onset of clinical symptoms; (4) Inoculation of the thus-obtained material into a viable embryo in an egg from a non-immune hen; and (5) Removal and treatment of brain tissue from the thus-infected normal live embryo to give the required vaccine. Preferred susceptible chicks are one day old, and cease to be susceptible over the age of 21 days.  Embryos used must be 4 to 6 days old in order not to be killed by the injection.  Treatment of the brain tissue suitably comprises addition of diluent buffer, preferably containing streptomycin, followed by homogenisation, cellular disintegration by ultrasonics, and centrifugation, to give a clear supernatant, to which is added glycerol.  Preferably treatment by ether extraction of the final embryo brain preparation is effected before the glycerol addition of this stage.  The vaccine may be administered orally, suitably at pH7, for example through the drinking water, to chicks above the age of 10 weeks.
A method for manufacturing the pharmaceutical composition based on Ciprofloxacin hydrochloride and Dexamethasone for ophthalmological and otological use comprises the dissolution of the surface-active substance, the moistening of glucocorticoid, sterilization, preparation and sterilization of the excipients, combination of the ingredients in sterile conditions. The composition is prepared with 0.09-0.20 % Dexamethasone and 0.20-0.40 % Ciprofloxacin hydrochloride. First, sodium chloride is dissolved in the water for injections at 0.45-0.9 % followed by the addition of Tiloxapol solution and micronized suspension of Dexamethasone. The suspension prepared is sterilized under the constant stirring. At the second step, hydroxyethyl cellulose is dissolved in the water for injections on being heated at the temperature of 55-. The solution is filtered and sterilized. At the third stage, the following ingredients are dissolved consecutively: sodium acetate trihydrate, glacial acetic acid, boric acid (to pH 3.8-4.8) and Ciprofloxacin hydrochloride. To the solution prepared, the solution of benzalconium chloride and disodium edentate prepared beforehand is added. The solution is further filtered through the membranes of 1 µm and 0.22 µm. The solutions prepared at the steps 2 and 3 are mixed aseptically. The suspension prepared at the step 1 is added. The suspension prepared is homogenized for 20-25 minutes.
The method for obtaining the equivalent of the corneal stroma for keratoplasty comprises the treatment of porcine cornea in the cell culture medium for decellularization. The treatment procedure is such as follows: The cornea is treated in a shaker with 0.5 % sodium dodecylsulfate at the temperature not more than 4 °C and sonicated for 5 minutes (CD 3800 A, 50 W). Then the sample is incubated with 0.1 % papaine (pH 6.5) for 2.5 hours at the temperature of 30 °C, washed in 0.1 M potassium phosphate buffer (pH 6.5) three times for 5 minutes. Then the sample is again sonicated for 5 minutes (CD 3800 A, 50 W) and treated with 0.5 % sodium dodecylsulfate twice for 3 hours, washed in 0.1 M potassium phosphate buffer (pH 6.5) three times for 5 minutes. Then the sample is again sonicated for 5 minutes (CD 3800 A, 50 W) and washed in 0.1 M potassium phosphate buffer (pH 6.5) five times for 5 minutes. The mixture is centrifuged at 3000 g for 15 minutes with decantation three times and transferred into the storage medium (2 % polyvinyl pyrrolidone) at the temperature of 0 °C.
Even in healthy populations, conditioned pain modulation (CPM) magnitude varies. This may be accounted for by (non-)modifiable factors, including physical activity (PA). Yet, little research has thoroughly examined PA and its relation with CPM magnitude in a representative sample. Therefore, the present study investigated the predictive effect of PA on CPM magnitude in 105 healthy adults. PA was assessed during 7 consecutive days by self-report using the International Physical Activity Questionnaire and by monitor-based accelerometry. CPM was examined using a heterotopic noxious-conditioning stimulation protocol during which the effect of a hot water-conditioning stimulus on pressure pain thresholds was evaluated. Comparative, correlation, and hierarchical linear regression analyses were performed. Report-based walking predicts 4.8% of variance in pain-modulatory capacity, moderate PA predicts 10.2% of variance in pain-modulatory capacity, and report-based time spent on total PA predicts 7.0% of variance in pain-modulatory capacity. More metabolic equivalent-minutes/week spent on total PA, including walking and moderate PA, is associated with greater pain-modulatory capacity. The findings of this study add to the limited evidence on the predictive effect of PA on CPM. It urges to consider PA a confounding factor when examining CPM. The current study provides evidence that a physically active lifestyle benefits endogenous pain modulation in healthy adults. Given its potential, walking and moderate-intensity PA might be achievable treatment strategies for pain patients known to have impaired CPM. PERSPECTIVE: The results of this article show that a physically active lifestyle, including larger amounts of walking and moderate activity, predicts greater pain-modulatory capacity. TRIAL REGISTRATION: This study has not been preregistered.
Glucocorticoids represent the mainstay of therapy for a broad spectrum of immune-mediated inflammatory diseases. However, the molecular mechanisms underlying their anti-inflammatory mode of action have remained incompletely understood1. Here we show that the anti-inflammatory properties of glucocorticoids involve reprogramming of the mitochondrial metabolism of macrophages, resulting in increased and sustained production of the anti-inflammatory metabolite itaconate and consequent inhibition of the inflammatory response. The glucocorticoid receptor interacts with parts of the pyruvate dehydrogenase complex whereby glucocorticoids provoke an increase in activity and enable an accelerated and paradoxical flux of the tricarboxylic acid (TCA) cycle in otherwise pro-inflammatory macrophages. This glucocorticoid-mediated rewiring of mitochondrial metabolism potentiates TCA-cycle-dependent production of itaconate throughout the inflammatory response, thereby interfering with the production of pro-inflammatory cytokines. By contrast, artificial blocking of the TCA cycle or genetic deficiency in aconitate decarboxylase 1, the rate-limiting enzyme of itaconate synthesis, interferes with the anti-inflammatory effects of glucocorticoids and, accordingly, abrogates their beneficial effects during a diverse range of preclinical models of immune-mediated inflammatory diseases. Our findings provide important insights into the anti-inflammatory properties of glucocorticoids and have substantial implications for the design of new classes of anti-inflammatory drugs.
The presence of a splenic subcapsular hematoma (SCH) has been associated with higher rates of failure of nonoperative management (FNOM) in patients with blunt splenic injury (BSI), with rates up to 80%. We hypothesized that contemporary rates are lower. A retrospective review was conducted of patients admitted with BSI to a level I trauma center (2016-2021). Patients with SCH who had FNOM were compared to those who did not. There were 661 BSI patients, of which 102 (15.4%) had SCH. Among the SCH patients, 8 (7.8%) had FNOM. Failure of nonoperative management was higher in patients who had a SCH measuring 15 mm or greater. To the best of our knowledge, this is the largest study to date examining the relationship between SCH and FNOM. The presence of a SCH alone is not associated with a high risk for FNOM contrary to previous literature. However, SCH thickness was larger in those who failed.
This is a single center study in HNSCC subjects to assess the effects of CRT on OSA.. Patients will be screened with a physical exam and questionnaire (The Berlin questionnaire, STOP-BANG, PSQI) and when eligible, will have the home sleep study (Specific aim 1). The low risk group (based on the physical exam and questionnaire) with stage IVc will not be eligible for the home sleep study and will concentrate on palliation of their symptoms. For locally advanced HNSCC patients undergoing definitive CRT, post CRT home sleep study results will also be assessed (Specific aim 2). When the patient is diagnosed with OSA based on the home sleep study, or if the home sleep study is negative but if the patient had high risks based on the screening process, the patient will be referred to the sleep medicine clinic. If life-threatening obstructive sleep apnea is found, the patient will be referred to sleep medicine clinic right away and will be taken off study. Otherwise, the patients will prioritize their definitive CRT for HNSCC, and will be referred to sleep medicine clinic once CRT has been completed.
Patients receive sunitinib malate PO QD on days 1-28 and hydroxychloroquine PO QD or BID on days 1-42 (beginning day 4 of course 1). Treatment repeats every 42 days for 6 courses in the absence of disease progression or unacceptable toxicity.
When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see Boxed Warning].

To reduce the potential risk of bleeding associated with the concurrent use of dabigatran etexilate and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of dabigatran [see Clinical Pharmacology (12.3)]. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of dabigatran is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.

Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.
The present invention is concerned with radiolabelled quinoline and quinolinone derivatives according to Formula (I-A)* or (I-B)* showing metabotropic glutamate receptor antagonistic activity, in particular mGlu1 receptor activity, and their preparation; it further relates to compositions comprising them, as well as their use for marking and identifying metabotropic glutamate receptor sites and for imaging an organ. In a preferable embodiment, ? represents O; R1 represents C1-6alkyl; cyclo3-12alkyl or (cycloC3-12alkyl)C1-6alkyl, wherein one or more hydrogen atoms in a C1-6alkyl-moiety or in a cycloC3-12alkyl-moiety optionally may he replaced by C1-6alkyloxy, aryl, halo or thienyl; R2 represents hydrogen; halo; C1-6alkyl or amino; R3 and R4 each independently represent hydrogen or C1-6alkyl; or R2 and R3 may he taken together to form -R2-R3-, which represents a bivalent radical of formula -Z4-CH2-CH2-CH2- or -Z4-CH2-CH2- with Z4 being O or NR11 wherein R11 is C1-6alkyl; and wherein each bivalent radical is optionally substituted with C1-6alkyl; or R3 and R4 may be taken together to form a bivalent radical of formula -CH2-CH2-CH2-CH2-; R5 represents hydrogen; ? represents O; and arylrepresents phenyl optionally substituted with halo. Most preferred are radiolabelled compounds in which the radioactive isotope is selected from the group of 3H, 11C and 18F. The invention also relates to their use in a diagnostic method, in particular for marking and identifying a mGluR1 receptor in biological material, as well as to their use for imaging an organ, in particular using PET.
PURPOSE:To obtain the titled composition having excellent drug-releasability and transcutaneous absorbability, exhibiting excellent remedying effect and free from side effects such as stimulation of gastric mucosa, by using a water- insoluble solid drug and a substance capable of dissolving the drug, e.g. benzyl alcohol, etc., as active components. CONSTITUTION:The objective composition contains, as active components, (A) a solid drug insoluble in water and (B) one or more substances capable of dissolving said drug and selected from benzyl alcohol, crotamiton, diphenhydramine, nicotinic acid ester, salicylic acid ester and a mixture of menthol and camphor. The amount of the water-insoluble solid drug in the composition is 0.01-5.0wt.% for steroidal anti-inflammatory agent and 0.5-5.0wt.% for non-steroidal anti-inflammatory agent. The amount of the component B is preferably 1-10pts.wt. or more based on 1pt.wt. of the solid drug.